New Risk • Aug 21
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr21m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr21m free cash flow). Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Revenue is less than US$1m (kr9.1m revenue, or US$961k). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (kr173.0m market cap, or US$18.3m). Aankondiging • Jul 22
Abera Bioscience AB to Report Q2, 2026 Results on Aug 20, 2026 Abera Bioscience AB announced that they will report Q2, 2026 results on Aug 20, 2026 New Risk • Jun 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Revenue is less than US$5m (kr12m revenue, or US$1.2m). Market cap is less than US$100m (kr174.7m market cap, or US$18.0m). New Risk • May 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$5m (kr12m revenue, or US$1.3m). Market cap is less than US$100m (kr135.7m market cap, or US$14.7m). Aankondiging • Apr 13
Abera Bioscience AB to Report Q1, 2026 Results on May 12, 2026 Abera Bioscience AB announced that they will report Q1, 2026 results on May 12, 2026 New Risk • Mar 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Revenue is less than US$5m (kr12m revenue, or US$1.3m). Market cap is less than US$100m (kr129.1m market cap, or US$13.7m). New Risk • Feb 17
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr17m revenue, or US$1.9m). Market cap is less than US$100m (kr132.2m market cap, or US$14.7m). Aankondiging • Jan 13
Abera Bioscience AB to Report Fiscal Year 2025 Results on Feb 12, 2026 Abera Bioscience AB announced that they will report fiscal year 2025 results on Feb 12, 2026 New Risk • Oct 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 28% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (kr16m revenue, or US$1.7m). Market cap is less than US$100m (kr117.1m market cap, or US$12.4m). Aankondiging • Oct 15
Abera Bioscience AB to Report Q3, 2025 Results on Nov 13, 2025 Abera Bioscience AB announced that they will report Q3, 2025 results on Nov 13, 2025 Aankondiging • Jul 23
Abera Bioscience AB to Report Q2, 2025 Results on Aug 21, 2025 Abera Bioscience AB announced that they will report Q2, 2025 results on Aug 21, 2025 Aankondiging • Apr 14
Abera Bioscience AB to Report Q1, 2025 Results on May 13, 2025 Abera Bioscience AB announced that they will report Q1, 2025 results on May 13, 2025 Aankondiging • Apr 10
Orexo Announces Positive In-Vivo Proof-Of-Concept Data for Powder-Based Intranasal Vaccine Formulated with the Amorphox Technology Orexo AB (publ.) announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences ("Abera") entered in December 2024. The proof-of-concept study was conducted in rats where Abera's influenza vaccine candidate was administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo's AmorphOX technology. Both formulations induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA). No difference in immune response was seen between the liquid nasal solution and the intranasal powder. An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic. Formulating vaccines in powder form using the AmorphOX technology provides the potential to develop cost-efficient, thermostable vaccines with no need for cold chain requirements. New Risk • Apr 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (kr69.5m market cap, or US$7.10m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.5m). New Risk • Feb 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.5m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (kr86.0m market cap, or US$8.04m). Minor Risk Revenue is less than US$5m (kr13m revenue, or US$1.2m). Aankondiging • Jan 15
Abera Bioscience AB to Report Fiscal Year 2024 Results on Feb 13, 2025 Abera Bioscience AB announced that they will report fiscal year 2024 results on Feb 13, 2025 New Risk • Nov 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.5m free cash flow). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (kr59.9m market cap, or US$5.45m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (6.1% increase in shares outstanding). Revenue is less than US$5m (kr13m revenue, or US$1.1m). Aankondiging • Oct 15
Abera Bioscience AB to Report Q3, 2024 Results on Nov 13, 2024 Abera Bioscience AB announced that they will report Q3, 2024 results on Nov 13, 2024 Aankondiging • Jul 23
Abera Bioscience AB to Report Q2, 2024 Results on Aug 21, 2024 Abera Bioscience AB announced that they will report Q2, 2024 results on Aug 21, 2024 Aankondiging • Apr 16
Abera Bioscience AB to Report Q1, 2024 Results on May 14, 2024 Abera Bioscience AB announced that they will report Q1, 2024 results on May 14, 2024 Aankondiging • Jan 24
Abera Bioscience AB to Report Fiscal Year 2023 Results on Feb 22, 2024 Abera Bioscience AB announced that they will report fiscal year 2023 results on Feb 22, 2024 Aankondiging • Oct 16
Abera Bioscience AB to Report Q3, 2023 Results on Nov 14, 2023 Abera Bioscience AB announced that they will report Q3, 2023 results on Nov 14, 2023 Aankondiging • Jul 18
Abera Bioscience AB to Report Q2, 2023 Results on Aug 16, 2023 Abera Bioscience AB announced that they will report Q2, 2023 results on Aug 16, 2023 Aankondiging • Jan 25
Abera Bioscience AB to Report Fiscal Year 2022 Results on Feb 23, 2023 Abera Bioscience AB announced that they will report fiscal year 2022 results on Feb 23, 2023 Board Change • Nov 16
No independent directors There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • May 24
Insider recently bought kr161k worth of stock On the 17th of May, Magnus Linderoth bought around 20k shares on-market at roughly kr7.88 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Feb 25
Abera Bioscience AB has completed an IPO in the amount of SEK 24.081 million. Abera Bioscience AB has completed an IPO in the amount of SEK 24.081 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 3,490,000
Price\Range: SEK 6.9
Transaction Features: Sponsor Backed Offering